研究業績

 

研究領域の参考のため2010年以降の代表的なものを掲載します

 

1.原著論文(和文論文は省略

1) Saito Y, Nishi T, Wakabayashi S, Ohno Y, Kitahara H, Ariyoshi N, Kobayashi Y. Validation of the ABCD-GENE score to identify high platelet reactivity in east Asian patients undergoing percutaneous coronary intervention.Int J Cardiol, 2020 Nov 19;S0167-5273(20)34145-0. doi: 10.1016/j.ijcard.2020.11.022.

2) Yamazaki K, Ariyoshi N, Miyauchi H, Ohira G, Kaneya N, Yamamoto K, Arai K, Yamazaki S, Matsubara H, Suzuki T, Ishii I. A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer.J Clin Pharm Ther, 44(6), 946-951 (2019)

3) San NS, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica, 49(8), 935-944(2019)

4) Matsumoto J, Nakamura H, San NS, Sato H, Takezawa M, Kishi R, Kito Y, Sugano J, Izuki M, Yanagisawa N, Ikeda N, Saito Y, Kato Y, Yamada H, Fujiyoshi M, Ariyoshi N. A proposed simple screening method to determine relative contributions of CYP3A4 and CYP3A5 to drug metabolism in vitro. Pers Med Univers. 8, 41-44 (2019)

5) Ohno Y, Kitahara H, Fujii K, Kohno Y, Ariyoshi N, Nishi T, Fujimoto Y, Kobayashi Y. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis.J Cardiol.73(1), 51-57 (2019)

6) Wakabayashi S, Ariyoshi N, Kitahara H, Fujii K, Fujimoto Y, Kobayashi Y. Efficacy of 2.5-mg Prasugrel in Elderly or Low-Body-Weight Patients.Circ J.82, 2326-2331 (2018)

7) San NS, Matsumoto J, Koike M, Saito Y, Sakaue H, Kato Y, Ariyoshi N, Yamada Y: Determination of sofosbuvir via a high-performance liquid chromatography method using ultraviolet detection. J Int Univ Health Welfare,23, 130-136(2018)

8) Maekawa M, Mori M, Fujiyoshi M, Suzuki H, Yanai K, Noda A, Tanaka M, Takasaki S, Kikuchi M, Akasaka K, Kisara S, Matsuura M, Hisamichi K, Sato M, Goto J, Shimada M, Yamaguchi H, Mano N. A Direct Injection LC/ESI-MS/MS Analysis of Urinary Cyclophosphamide as an Anticancer Drug for Monitoring Occupational Exposure. Chromatography, 39, 41-47 (2018)

9) Honzumi S, Takeuchi M, Kurihara M, Fujiyoshi M, Uchida M, Watanabe K, Suzuki T, Ishii I. The effect of cholesterol overload on mouse kidney and kidney-derived cells. Ren Fail. 40, 43-50 (2018)

10) Wakabayashi S, Kitahara H, Nishi T, Sugimoto K, Nakayama T, Fujimoto Y, Ariyoshi N, Kobayashi Y. Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. Cardiovasc Interv Ther. 33, 239-246 (2018)

11) Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Wakabayashi S, Hanaoka H, Kobayashi Y. Impact of Chronic Kidney Disease on Platelet Inhibition of Clopidogrel and Prasugrel in Japanese Patients.J. Cardiol.69,752-755 (2017)

12) Kanogawa Y, Fujiyoshi M, Nakazato Y, Watanabe K, Kurihara M, Takezawa A, Uchida M, Igarashi K, Suzuki T, Ariyoshi N, Ishii I: Beta-migrating very low-density lipoprotein conjugates with acrolein in high-cholesterol diet-fed rabbits and localizes to atherosclerotic lesions with macrophages. Int J Clin Exp Pathol. 9, 11149-11158 (2016)

13) Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Takahara M, Wakabayashi S, Koshizaka M, Hanaoka H, Kobayashi Y. Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Japanese Patients With Stable Coronary Artery Disease. Circ J.79, 2439-2444 (2015)

14) Matsumoto J, Ariyoshi N, Sakakibara M, Nakanishi T, Okubo Y, Shiina N, Fujisaki K, Nagashima T, Nakatani Y, Tamai I, Yamada H, Takeda H, Ishii I. Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells. Drug Metab Pharmacokinet. 30, 133-141 (2015)

15) Miura G, Ariyoshi N, Sato Y, Yamaguchi H, Iwata Y, Fujimoto Y, Kobayshi Y, Ishii I. Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity.Thromb Res.134, 877-883 (2014)

16) Uchiyama K, Kubota F, Ariyoshi N, Matsumoto J, Ishii I, Kitada M. Development of a simple method for detection of HLA-A*31:01 allele.Drug Metab Pharmacokinet.28, 435-438 (2013)

17) Matsumoto J, Ariyoshi N, Ishii I, Kitada M. Functional characterization of seven single nucleotide polymorphisms of the steroid sulfatase gene found in a Japanese population.J Hum Genet.58, 267-272 (2013)

18) Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, Nakamura H, Ishii I, Ishikawa T, Kitada M. Glu172His replacement overcomes effects on the metabolism of cyclophosphamide and efevirenz caused by CYP2B6 variant with Arg262.Drug Metab. Dispos.39, 2045-2048 (2011)

19) Matsumoto J, Ariyoshi N, Ishii I, Kitada M. Six Novel Single Nucleotide Polymorphisms of the Steroid Sulfatase Gene in a Japanese Population. Drug Metab Pharmacokinet.25, 403-407 (2010)

20) Harada T, Ariyoshi N, Shimura H, Sato Y, Yokoyama I, Takahashi K, Yamagata SI, Imamaki M, Kobayashi Y, Ishii I, Miyazaki M, Kitada M. Application of Akaike information criterion to evaluate warfarin dosing algorithm. Thromb Res. 126, 183-190 (2010)

21) Ariyoshi N, Iga Y, Hirata K, Sato Y, Miura G, Ishii I, Nagamori S, Kitada M. Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab Pharmacokinet.25, 298-306 (2010)

 

2.総説

1) 有吉範高(2016)注意したいCYP2C19,2D6における薬物相互作用を教えてください,月刊薬事,58(4): 68-72.

2) 有吉範高(2016)注意したいCYP1A2,2C9,他のCYPにおける薬物相互作用を教えてください,月刊薬事,58(4): 63-67.

3) 有吉範高(2016)個別化医療の展望.HAB Newsletter,22(2): 4-5.

4) Ariyoshi, N. Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs.Pers Med Univers.4, 13-22 (2015)

5) 有吉範高(2013)遺伝子検査と薬物治療. 日病薬誌, 40: 1-7.

6) 有吉範高(2013)簡易遺伝子診断法の開発・実臨床への適用による医薬品適正使用の推進. 医療薬学, 39: 61-76.

7) 有吉範高(2012)薬物治療とpharmcogenetics. アレルギー, 61: 941-947.

8) 有吉範高(2012)薬剤師が始める臨床現場での遺伝子診断,月刊薬事,54(6),975-97.

9) 長谷川 敦,有吉範高(2010)代謝酵素が関係した相互作用④イトラコナゾールとCYP3A4代謝薬剤,薬局,61(8),56-61.

 

3.著書

1) 有吉範高(2018)ファーマコゲノミクスとは? ここが知りたい - 遺伝子診療BOOK, 中外医学社, 290-292.

2) 有吉範高(2018)ファーマコゲノミクスは薬物の副作用回避や投与量の調節にいかに役立っているか?ここが知りたい - 遺伝子診療BOOK, 中外医学社, 293-297.

3) 有吉範高(2015)薬物代謝酵素・薬物トランスポーター多型診断の臨床的意義,遺伝子医学 ますます臨床利用が進む遺伝子検査-その現状と今後の展望そして課題-, メディカル ドゥ, 110-116.

4) 有吉範高(2015)生殖細胞系列PGx,日常診療のための検査値のみかた,野村文夫・村上正己・和田隆志・末岡栄三朗編,中外医学社, 620-624.

5) 有吉範高(2013)抗がん薬の臨床薬理,抗がん薬の毒性学,相羽惠介編,南山堂, 128-140.

6) 有吉範高(2011)テーラーメイド医療,医薬品情報・評価学 第3版,河島進・政田幹夫編,南江堂,131-146.

7) 有吉範高(2010)悪性腫瘍,薬剤師のための疾患別薬物療法I,医療薬学会編(担当編集 有吉 範高),南江堂, 1-131.

8) 有吉範高(2010)肝・胆・膵疾患の治療薬,疾患と治療薬 改訂第6版,南江堂,293-323.